Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Recommendation of "Hold" from Analysts

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has received an average rating of "Hold" from the five ratings firms that are covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $17.00.

Several equities analysts have weighed in on the company. Cowen cut Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. TD Cowen lowered Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 1st. TD Securities lowered Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Finally, HC Wainwright restated a "buy" rating and issued a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Friday, March 28th.

Milestone Pharmaceuticals Price Performance

Shares of MIST stock traded up $0.01 during midday trading on Thursday, reaching $1.39. 254,431 shares of the company were exchanged, compared to its average volume of 891,526. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $2.75. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The company has a market cap of $74.05 million, a P/E ratio of -1.71 and a beta of 0.86. The company's 50 day moving average price is $1.22 and its two-hundred day moving average price is $1.70.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). On average, sell-side analysts expect that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Propel Bio Management LLC bought a new stake in shares of Milestone Pharmaceuticals during the 1st quarter worth $1,161,000. Toronto Dominion Bank acquired a new stake in Milestone Pharmaceuticals in the 4th quarter valued at approximately $1,770,000. Boxer Capital Management LLC bought a new position in Milestone Pharmaceuticals in the 4th quarter worth approximately $729,000. Walleye Capital LLC acquired a new position in shares of Milestone Pharmaceuticals during the first quarter worth approximately $74,000. Finally, Virtu Financial LLC bought a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at approximately $170,000. 86.18% of the stock is owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.